SomniTR provides support for patients with sleep.It is a delayed-release formula designed to initially release 1 mg of melatonin immediately after ingestion and 1 mg three hours later to help the patient stay asleep longer.* SomniTR supports optimal melatonin production by supplementing multiple steps in the serotonin-to-melatonin pathway and also influences inhibitory GABAergic activity.* The delayed–release melatonin in SomniTR provides sustained levels for up to eight hours. It also provides support for GABA-A receptor sites.* GABA-A agonists, such as Lactium have been shown to improve quality of sleep.* ForsLean supports cAMP while pantothenic acid supports acetyl coenzyme A, both of which are important in melatonin synthesis.*

† These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.